MCP AbD Serotec
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/mcp.M700263-MCP200 on December 11, 2007.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
M700263-MCP200v1
7/3/600    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Glossary
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taylor, B. S.
Right arrow Articles by Sreekumar, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, B. S.
Right arrow Articles by Sreekumar, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular & Cellular Proteomics 7:600-611, 2008.
© 2008 by The American Society for Biochemistry and Molecular Biology, Inc.


Research

Humoral Response Profiling Reveals Pathways to Prostate Cancer Progression*,S

Barry S. Taylora,b,c,d, Manoj Pale, Jianjun Yua,b,c, Bharathi Laxmana,b, Shanker Kalyana-Sundarama,b, Rong Zhaoa,b, Anjana Menona,b, John T. Weif,g, Alexey I. Nesvizhskiia,c, Debashis Ghoshc,h, Gilbert S. Omennc,i, David M. Lubmane,g,j, Arul M. Chinnaiyana,b,c,f,g,k,l and Arun Sreekumara,b,g,k,m

From the a Michigan Center for Translational Pathology, Departments of b Pathology, f Urology, c Bioinformatics Program/Center for Computational Medicine and Biology, h Biostatistics, e Chemistry, j Surgery, and i Internal Medicine, and the g Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan 48109

There is considerable evidence for an association between prostate cancer development and inflammation, which results in autoantibody generation against tumor proteins. This immune system-driven amplification of the autoantibody response to intracellular antigens can serve as a sensitive tool to detect low abundance serum proteomic tumor markers for prostate cancer as well as provide insight into biological processes perturbed during cancer development. Here we examine serum humoral responses in a cohort of 34 patients with either benign prostatic hyperplasia or clinically localized prostate cancer (PCa). The experimental strategy couples multidimensional liquid-phase protein fractionation of localized and metastatic prostate cancer tissue lysates to protein microarrays and subsequent mass spectrometry. A supervised learning analysis of the humoral response arrays generated a parsimonious predictor having 78% sensitivity and 75% specificity in distinguishing PCa from benign prostatic hyperplasia in a cohort of American males with elevated prostate-specific antigen. Enrichment analysis of the PCa-specific humoral signature revealed large scale immune reprogramming mediated by STAT transcription factors and the generation of autoantibodies to enzymes involved in nitrogen metabolism. Meta-analysis of independent prostate cancer gene expression data validated the presence of STAT-induced immunomodulation. Concomitant validation of elevated levels of the nitrogen metabolism pathway was obtained by direct measurement of metabolic levels of glutamate and aspartate in prostate cancer tissues. Thus, in addition to functioning as markers in prostate cancer detection, humoral response profiles can serve as powerful tools revealing pathway dysregulation that might otherwise be suppressed by the complexity of the cancer proteome.


m Supported by a grant from the Fund for Discovery of the University of Michigan Comprehensive Cancer Center. To whom correspondence should be addressed: Dept. of Pathology, University of Michigan Medical School, 1150 West Medical Center Dr., 4510D MSRB1, Ann Arbor, MI 48109. Tel.: 734-615-1407; Fax: 734-763-6476; E-mail: asreekum{at}umich.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Clin. Chem.Home page
G. Sardana, B. Dowell, and E. P. Diamandis
Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer
Clin. Chem., December 1, 2008; 54(12): 1951 - 1960.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.